Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced that the FDA cleared an Investigational New Drug application (IND) for a clinical trial evaluating the safety and efficacy …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced positive results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced its financial results for the full-year ended December 31, 2016, and provided a corporate update. “Recently, our Executive Vice …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) shares surged nearly 10% in Friday’s trading session, after Canadian specialty pharmaceutical firm Knight Therapeutics announced that it has acquired 6,200,000 common shares of …
Protalix BioTherapeutics Inc. (NYSEMKT:PLX) positive clinical study results from the Company’s Phase I trial of PRX-106, an orally administered plant cell-expressed recombinant anti-TNF fusion …
Protalix BioTherapeutics Inc. (NYSE MKT:PLX) announced that pre-clinical data for AIR DNaseTM (PRX-110) for the treatment of Cystic Fibrosis will be presented at …
Protalix BioTherapeutics Inc. (NYSEMKT:PLX) reported financial results for the quarter ended March 31, 2015.
